FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. More Details
Flawless balance sheet and slightly overvalued.
Share Price & News
How has FibroGen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FGEN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: FGEN's weekly volatility has increased from 10% to 16% over the past year.
7 Day Return
1 Year Return
Return vs Industry: FGEN underperformed the US Biotechs industry which returned 25.3% over the past year.
Return vs Market: FGEN underperformed the US Market which returned 51.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is FibroGen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShould You Take Comfort From Insider Transactions At FibroGen, Inc. (NASDAQ:FGEN)?
1 month ago | Simply Wall StDoes FibroGen (NASDAQ:FGEN) Have A Healthy Balance Sheet?
2 months ago | Simply Wall StThe Consensus EPS Estimates For FibroGen, Inc. (NASDAQ:FGEN) Just Fell Dramatically
Is FibroGen undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FGEN ($20.23) is trading below our estimate of fair value ($152.81)
Significantly Below Fair Value: FGEN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: FGEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FGEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FGEN is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (3.4x).
How is FibroGen forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FGEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FGEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FGEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FGEN's revenue (21.3% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: FGEN's revenue (21.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FGEN's Return on Equity is forecast to be high in 3 years time
How has FibroGen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FGEN is currently unprofitable.
Growing Profit Margin: FGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FGEN is unprofitable, and losses have increased over the past 5 years at a rate of 14.3% per year.
Accelerating Growth: Unable to compare FGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).
Return on Equity
High ROE: FGEN has a negative Return on Equity (-42.88%), as it is currently unprofitable.
How is FibroGen's financial position?
Financial Position Analysis
Short Term Liabilities: FGEN's short term assets ($755.1M) exceed its short term liabilities ($163.2M).
Long Term Liabilities: FGEN's short term assets ($755.1M) exceed its long term liabilities ($222.2M).
Debt to Equity History and Analysis
Debt Level: FGEN's debt to equity ratio (4.2%) is considered satisfactory.
Reducing Debt: FGEN's debt to equity ratio has reduced from 7.4% to 4.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable FGEN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: FGEN is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 9.1% per year.
What is FibroGen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Enrique Conterno (53 yo)
Mr. Enrique A. Conterno is the Chief Executive Officer and Director at FibroGen, Inc. since January 6, 2020. He served as President of Lilly USA from January 2017 to 2019. Mr. Conterno served as President ...
CEO Compensation Analysis
Compensation vs Market: Enrique's total compensation ($USD12.27M) is above average for companies of similar size in the US market ($USD3.76M).
Compensation vs Earnings: Insufficient data to compare Enrique's compensation with company performance.
Experienced Management: FGEN's management team is considered experienced (3.7 years average tenure).
Experienced Board: FGEN's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.3%.
FibroGen, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: FibroGen, Inc.
- Ticker: FGEN
- Exchange: NasdaqGS
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.900b
- Shares outstanding: 92.07m
- Website: https://www.fibrogen.com
Number of Employees
- FibroGen, Inc.
- 409 Illinois Street
- San Francisco
- United States
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibito...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 23:42|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.